Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Issue 10 (17th May 2012)

• Record Type: Journal Article
• Authors: Bakker, Marije F; Cavet, Guy; Jacobs, Johannes WG; Bijlsma, Johannes W J; Haney, Douglas J; Shen, Yijing; Hesterberg, Lyndal K; Smith, Dustin R; Centola, Michael; van Roon, Joel A G; Lafeber, Floris P J G; Welsing, Paco M J
• Is Part Of: Annals of the rheumatic diseases. Volume 71:Issue 10(2012)
• Page Start: 1692
• Page End: 1697
• Publication Date: 2012-05-17
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2011-200963
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: To evaluate the performance of individual biomarkers and a multi-biomarker disease activity (MBDA) score in the early rheumatoid arthritis (RA) patient population from the computer assisted management in early rheumatoid arthritis (CAMERA) study. Methods: Twenty biomarkers were measured in the CAMERA cohort, in which patients were treated with either intensive or conventional methotrexate-based treatment strategies. The MBDA score was calculated using the concentrations of 12 biomarkers (SAA, IL-6, TNF-RI, VEGF-A, MMP-1, YKL-40, MMP-3, EGF, VCAM-1, leptin, resistin and CRP) according to a previously trained algorithm. The performance of the scores was evaluated relative to clinical disease activity assessments. Change in MBDA score over time was assessed by paired Wilcoxon rank sum test. Logistic regression was used to evaluate the ability of disease activity measures to predict radiographic progression. Results: The MBDA score had a significant correlation with the disease activity score based on 28 joints-C reactive protein (DAS28-CRP) (r=0.72; p<0.001) and an area under the receiver operating characteristic curve for distinguishing remission/low from moderate/high disease activity of 0.86 (p<0.001) using a DAS28-CRP cut-off of 2.7. In multivariate analysis the MBDA score, but not CRP, was an independent predictor of disease activity measures. Additionally, mean (SD) MBDA score decreased from 53 (18) at baseline to 39 (16) at 6 months in response to study therapy (p<0.0001). Neither MBDA score nor clinical variables were predictive of radiographic progression. Conclusions: This multi-biomarker test performed well in the assessment of disease activity in RA patients in the CAMERA study. Upon further validation, this test could be used to complement currently available disease activity measures and improve patient care and outcomes.